Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo

European Journal of Pharmacology

Volumn 744, Issue , 2015, Pages 98-102

  Jung, Eunsoo ^a,b   Kim, Junghyun ^c   Kim, Sung Ho ^b   Kim, Sanghwa ^a   Cho, Myung Haing ^a,d  

^a Seoul National University   (South Korea)

^b LG Chemical Ltd   (South Korea)

^c Korea Institute of Oriental Medicine (KIOM)   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

Advanced glycation end products (AGEs); Gemigliptin; Glycation; Methyglyoxal

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; BOVINE SERUM ALBUMIN; COLLAGEN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GEMIGLIPTIN; GLUCOSE; METHYLGLYOXAL; ADVANCED GLYCATION END PRODUCTS-BOVINE SERUM ALBUMIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; LC15-0444; PIPERIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; GLUCOSE BLOOD LEVEL; GLYCATION; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN CROSS LINKING; ANIMAL; C57BL MOUSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLYCOSYLATION; METABOLISM; RAT;

ANIMALS; COLLAGEN; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENZYME INHIBITORS; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; PIPERIDONES; PYRIMIDINES; RATS; SERUM ALBUMIN, BOVINE;

EID: 84918819081     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.10.008     Document Type: Article

References (29)

1. M. Bourajjaj, C.D. Stehouwer, V.W. van Hinsbergh, and C.G. Schalkwijk Role of methylglyoxal adducts in the development of vascular complications in diabetes mellitus Biochem. Soc. Trans. 31 2003 1400 1402
2. M. Brownlee Advanced protein glycosylation in diabetes and aging Annu. Rev. Med. 46 1995 223 234
3. M. Brownlee, A. Cerami, and H. Vlassara Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications N. Engl. J. Med. 318 1988 1315 1321
4. D. Edelstein, and M. Brownlee Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine Diabetes 41 1992 26 29
5. G.M. Haik Jr., T.W. Lo, and P.J. Thornalley Methylglyoxal concentration and glyoxalase activities in the human lens Exp. Eye Res. 59 1994 497 500
6. H.P. Hammes, S. Martin, K. Federlin, K. Geisen, and M. Brownlee Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy Proc. Natl. Acad. Sci. U S A 88 1991 11555 11558
7. P.G. Horan, M.S. Kamaruddin, M.J. Moore, D. McCarty, M.S. Spence, P.G. McGlinchey, G. Murphy, T.C. Jardine, C.C. Patterson, and P.P. McKeown Cardiovascular disease risk profiles among 'healthy' siblings of patients with early-onset cardiovascular disease: application of the new SCORE system Eur. J. Cardiovasc. Prev. Rehabil. 14 2007 521 525
8. J. Kim, I.H. Jeong, C.S. Kim, Y.M. Lee, J.M. Kim, and J.S. Kim Chlorogenic acid inhibits the formation of advanced glycation end products and associated protein cross-linking Arch. Pharm. Res. 34 2011 495 500
9. K. Kumari, S. Umar, V. Bansal, and M.K. Sahib Inhibition of diabetes-associated complications by nucleophilic compounds Diabetes 40 1991 1079 1084
10. T.W. Lo, T. Selwood, and P.J. Thornalley The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins Biochem. Pharmacol. 48 1994 1865 1870
11. T. Matsui, Y. Nishino, M. Takeuchi, and S. Yamagishi Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis Pharmacol. Res. 63 2011 383 388
12. S. Miyata, B.F. Liu, H. Shoda, T. Ohara, H. Yamada, K. Suzuki, and M. Kasuga Accumulation of pyrraline-modified albumin in phagocytes due to reduced degradation by lysosomal enzymes J. Biol. Chem. 272 1997 4037 4042
13. Y. Moritoh, K. Takeuchi, T. Asakawa, O. Kataoka, and H. Odaka Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice Br. J. Pharmacol. 157 2009 415 426
14. T. Nagakura, N. Yasuda, K. Yamazaki, H. Ikuta, and I. Tanaka Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition Metabolism 52 2003 81 86
15. R.H. Nagaraj, P. Sarkar, A. Mally, K.M. Biemel, M.O. Lederer, and P.S. Padayatti Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal Arch. Biochem. Biophys. 402 2002 110 119
16. R.S. Pandit, A.S. Kelkar, and S.L. Bodhankar Retinal and lens protective effect of sitagliptin in streptozotocin induced type-I diabetic wistar rats Biomed. Aging Pathol. 3 2013 65 73
17. S. Pennock, D. Kim, S. Mukai, M. Kuhnle, D.W. Chun, J. Matsubara, J. Cui, P. Ma, D. Maberley, A. Samad, R.J. Van Geest, S.L. Oberstein, R.O. Schlingemann, and A. Kazlauskas Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease Am. J. Pathol. 182 2013 1659 1670
18. S. Rahbar, and J.L. Figarola Novel inhibitors of advanced glycation endproducts Arch. Biochem. Biophys. 419 2003 63 79
19. M. Safavi, A. Foroumadi, and M. Abdollahi The importance of synthetic drugs for type 2 diabetes drug discovery Expert Opin. Drug Discov. 8 2013 1339 1363
20. T. Sato, M. Iwaki, N. Shimogaito, X. Wu, S. Yamagishi, and M. Takeuchi TAGE (toxic AGEs) theory in diabetic complications Curr. Mol. Med. 6 2006 351 358
21. F.A. Shamsi, A. Partal, C. Sady, M.A. Glomb, and R.H. Nagaraj Immunological evidence for methylglyoxal-derived modifications in vivo. Determination of antigenic epitopes J. Biol. Chem. 273 1998 6928 6936
22. K. Shima, M. Komatsu, Y. Noma, and K. Miya Glycated Albumin (GA) is more advantageous than hemoglobin A1c for evaluating the efficacy of sitagliptin in achieving glycemic control in patients with type 2 diabetes Intern. Med. 53 2014 829 835
23. G. Suji, and S. Sivakami DNA damage by free radical production by aminoguanidine Ann. N. Y. Acad. Sci. 1067 2006 191 199
24. P.J. Thornalley Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts Arch. Biochem. Biophys. 419 2003 31 40
25. P.J. Thornalley, A. Yurek-George, and O.K. Argirov Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions Biochem. Pharmacol. 60 2000 55 65
26. R.G. Tilton, K. Chang, K.S. Hasan, S.R. Smith, J.M. Petrash, T.P. Misko, W.M. Moore, M.G. Currie, J.A. Corbett, and M.L. McDaniel Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation Diabetes 42 1993 221 232
27. F. Turgut, and W.K. Bolton Potential new therapeutic agents for diabetic kidney disease Am. J. Kidney Dis. 55 2010 928 940
28. D.M. Vardhan, C.S. Shantharam, R. Suhas, M.B. Sridhara, and D.C. Gowda Synthesis and SAR studies of urea and thiourea derivatives of gly/pro conjugated to piperazine analogue as potential AGE inhibitors Protein Pept. Lett. 20 2013 888 897
29. S. Vasan, X. Zhang, A. Kapurniotu, J. Bernhagen, S. Teichberg, J. Basgen, D. Wagle, D. Shih, I. Terlecky, R. Bucala, A. Cerami, J. Egan, and P. Ulrich An agent cleaving glucose-derived protein crosslinks in vitro and in vivo Nature 382 1996 275 278